Zollinger‑Ellison syndrome (gastrinoma-associated duodenal ulcer) - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Gastrinoma‑Associated Duodenal Ulcer) – Complete Guide

Zollinger‑Ellison Syndrome (Gastrinoma‑Associated Duodenal Ulcer)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas produce excessive amounts of the hormone gastrin. The surplus gastrin stimulates the stomach lining to secrete large volumes of gastric acid, leading to severe, recurrent duodenal (and sometimes gastric) ulcers and a range of gastrointestinal symptoms.

Who it affects: ZES can occur at any age but most commonly presents in adults aged 30–60 years. There is a slight male predominance (about 55 % male). Approximately 20–25 % of cases are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN‑1), while the remaining cases are sporadic.

Prevalence: The exact prevalence is uncertain because many cases remain undiagnosed, but estimates from population‑based studies suggest an incidence of 0.5–2 cases per million persons per year in the United States and Europe, making ZES one of the rarest functional neuroendocrine tumors.[1]

Symptoms

Symptoms result from high gastric acid output, ulcer formation, and occasionally tumor‑related effects. The presentation may be subtle at first and then progress to severe disease.

Gastro‑intestinal symptoms

  • Recurrent duodenal ulcer pain – burning or gnawing epigastric pain that may improve with food (unlike typical peptic ulcer disease) or worsen after meals.
  • Gastric ulcer pain – similar to duodenal ulcer but located higher in the stomach.
  • Diarrhea – watery, sometimes greasy stools due to acid inactivation of pancreatic enzymes.
  • Steatorrhea (fatty stools) – malabsorption of fat because acid damages the mucosal brush border.
  • Weight loss – secondary to malabsorption, chronic pain, and reduced intake.
  • Nausea and vomiting – especially after large meals.
  • Gastro‑esophageal reflux disease (GERD) – acid reflux can be severe.
  • Abdominal bloating or distension.

Systemic / extra‑intestinal symptoms

  • Fatigue – from chronic anemia due to occult GI bleeding.
  • Iron‑deficiency anemia – iron loss from ulcer bleeding.
  • Kidney stones – hypercalciuria can develop in MEN‑1 patients.
  • Hormone‑related manifestations (if MEN‑1) – hyperparathyroidism, pituitary tumors, or other endocrine abnormalities.

Causes and Risk Factors

Underlying cause

ZES is caused by a gastrin‑secreting neuroendocrine tumor (gastrinoma) that is most often located in the “gastrinoma triangle” – the duodenum, pancreas, and the junction of the two (the superior mesenteric artery origin). The tumor may be benign or malignant; roughly 60 % are malignant at diagnosis.[2]

Risk factors

  • MEN‑1 syndrome – inherited mutation in the MEN1 gene; confers a 20–25 % lifetime risk of gastrinoma.
  • Family history of ZES or MEN‑1.
  • Age – peak incidence in the fourth to sixth decades.
  • History of chronic gastritis or H. pylori infection – does not cause ZES but can mask symptoms and delay diagnosis.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is required, especially when ulcers are refractory to standard therapy.

Initial laboratory evaluation

  • Fasting serum gastrin level – markedly elevated (>1000 pg/mL) in most ZES patients. Levels <200 pg/mL are usually not diagnostic unless the acid output is extremely high.
  • Secretin stimulation test – administration of secretin paradoxically raises gastrin in gastrinoma patients (increase ≥120 pg/mL). This test has a sensitivity of 94 % and specificity of 100 % for ZES.[3]
  • pH testing – gastric pH <2 confirms hyperacidity.
  • Chromogranin A – a neuroendocrine marker that may be elevated.

Imaging studies

  • Endoscopic ultrasound (EUS) – high‑resolution imaging of the duodenum and pancreas; detects tumors as small as 5 mm.
  • Multiphasic contrast‑enhanced CT or MRI – assesses tumor size, location, and metastatic spread (liver, lymph nodes).
  • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – functional imaging that highlights neuroendocrine tumors expressing somatostatin receptors; valuable for staging and surgical planning.
  • Selective arterial secretin stimulation test – rarely used; helps localize occult gastrinomas.

Endoscopy

Upper endoscopy (EGD) is performed to document ulcer disease, obtain biopsies to rule out malignancy, and occasionally locate duodenal gastrinomas that may be submucosal.

Treatment Options

Management aims to control acid hypersecretion, eradicate or control the tumor, and address complications.

Acid‑suppression therapy (first‑line)

  • High‑dose proton‑pump inhibitors (PPIs) – omeprazole 60–80 mg daily, esomeprazole 40 mg BID, or equivalent. PPIs normalize gastric pH, heal ulcers, and improve quality of life in >90 % of patients.[4]
  • Potassium‑competitive acid blockers (P‑CABs) – e.g., vonoprazan (available in some countries) may be considered for refractory cases.
  • PPIs are usually required lifelong unless the gastrinoma is cured surgically.

Surgical management

  • Enucleation or limited resection – preferred for isolated, small (<2 cm) duodenal or pancreatic gastrinomas.
  • Pancreaticoduodenectomy (Whipple procedure) – indicated for larger or infiltrative pancreatic tumors.
  • Debulking surgery – for metastatic disease; may reduce tumor burden and gastrin production.
  • Surgery offers a potential cure in 30–40 % of sporadic cases and 10–15 % of MEN‑1‑associated cases.[5]

Medical therapies for tumor control

  • Somatostatin analogues (octreotide or lanreotide) – bind somatostatin receptors, inhibit gastrin release, and can stabilize tumor growth.
  • Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive metastatic neuroendocrine tumors.
  • Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for patients with high somatostatin‑receptor expression and refractory disease.
  • Chemotherapy – used rarely; reserved for poorly differentiated, high‑grade neuroendocrine carcinomas.

Lifestyle and supportive measures

  • Avoid NSAIDs, aspirin, and other ulcer‑promoting drugs unless absolutely necessary.
  • Limit alcohol and caffeine, which can stimulate acid secretion.
  • Adopt a low‑fat diet if steatorrhea occurs; supplement with pancreatic enzymes if needed.
  • Maintain adequate calcium and vitamin D intake; monitor bone density, especially in MEN‑1 patients.

Living with Zollinger‑Ellison Syndrome (gastrinoma‑associated duodenal ulcer)

Long‑term management focuses on symptom control, adherence to medication, and regular monitoring.

Medication adherence

  • Take PPIs exactly as prescribed – usually once or twice daily, 30 minutes before a meal.
  • Carry a short‑acting antacid (e.g., calcium carbonate) for breakthrough symptoms.

Follow‑up schedule

  • Every 3–6 months: Clinical review, serum gastrin level, and PPI dose adjustment.
  • Annually: Imaging (CT/MRI or Ga‑68 DOTATATE PET/CT) to detect tumor progression.
  • For MEN‑1 patients, coordinate care with endocrinology, genetics, and surgery.

Nutrition tips

  • Eat smaller, frequent meals to reduce acid load.
  • Incorporate complex carbohydrates and lean protein; avoid spicy, fried, or highly acidic foods.
  • If fat malabsorption persists, discuss pancreatic enzyme replacement with your gastroenterologist.

Psychosocial support

Living with a chronic, rare disease can be stressful. Consider joining patient support groups (e.g., Neuroendocrine Tumor Research Foundation) and seeking counseling if anxiety or depression develops.

Prevention

Because most gastrinomas arise spontaneously, primary prevention is limited. However, certain steps can reduce the risk of complications and improve outcomes:

  • Screen individuals with known MEN‑1 mutations early (starting around age 10) using fasting gastrin levels and imaging.
  • Avoid chronic use of ulcer‑causing medications (NSAIDs, high‑dose steroids) unless protective PPIs are co‑prescribed.
  • Eradicate Helicobacter pylori infection if present – it does not cause ZES but can worsen ulcer disease.
  • Adopt a healthy lifestyle (balanced diet, no smoking, limited alcohol) to support overall gastrointestinal health.

Complications

Without appropriate treatment, persistent hyperacidity and tumor growth can lead to serious problems:

  • Perforated duodenal ulcer – life‑threatening abdominal emergency.
  • Upper gastrointestinal bleeding – melena or hematemesis; may cause anemia.
    • Malnutrition – due to chronic diarrhea, steatorrhea, and poor absorption of nutrients.
  • Gastrointestinal strictures – from repeated ulcer healing.
  • Metastatic disease – liver, lymph nodes, or bone involvement in up to 60 % of sporadic cases at diagnosis.[6]
  • Pancreatitis – from tumor invasion of pancreatic tissue.
  • MEN‑1‑related endocrine complications – hyperparathyroidism, pituitary adenomas, adrenal lesions.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with your usual medications.
  • Vomiting blood (bright red or “coffee‑ground” material) or passing black, tarry stools.
  • Faintness, rapid heartbeat, or a sudden drop in blood pressure – possible signs of major bleeding.
  • High‑grade fever (>101 °F/38.3 °C) with abdominal pain – may indicate perforation or infection.
  • Sudden onset of difficulty breathing or severe choking sensation after vomiting.
Prompt treatment can be life‑saving.

References

  1. Bonin E, et al. Zollinger‑Ellison syndrome: current concepts. *Int J Surg*. 2017.
  2. Mullani N, et al. Clinical management of ZES. *Cancer Network*. 2020.
  3. Thompson LJ, et al. Secretin stimulation test for gastrinoma diagnosis. *Gastroenterology*. 2019.
  4. Mayo Clinic – Zollinger‑Ellison syndrome: Diagnosis & treatment.
  5. Cleveland Clinic – Zollinger‑Ellison syndrome overview.
  6. Khan S, et al. Management of metastatic gastrinoma. *World J Gastroenterol*. 2020.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References